Related Experiment Video

Updated: Mar 8, 2026

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

960

Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes

Samuel Jang1,2, Xiao-Min Yu1, Celina Montemayor-Garcia3

  • 1Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Oncotarget
|February 5, 2017
PubMed
Abstract

Insights

The antibody-drug conjugate EDC1 targets dysadherin on thyroid cancer cells. This study found EDC1 effectively inhibits growth in thyroid cancer cell lines expressing dysadherin, showing therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Dysadherin is a surface protein expressed on cancer cells.
  • EDC1 is a novel antibody-drug conjugate targeting Na,K-ATPase.
  • Dysadherin expression is investigated as a potential therapeutic target in thyroid cancer.

Purpose of the Study:

  • To determine dysadherin expression in various thyroid carcinoma types.
  • To evaluate the therapeutic potential of EDC1 for thyroid carcinomas.

Main Methods:

  • Dysadherin expression was analyzed in 158 thyroid tissue samples.
  • Correlation of dysadherin expression with clinicopathological features was assessed.
  • Thyroid cancer cell lines were tested for dysadherin expression and sensitivity to EDC1.

Main Results:

  • Dysadherin was expressed in 62% of thyroid cancers, with higher prevalence in anaplastic and papillary types.
  • Dysadherin expression correlated with extrathyroidal extension and lymph node metastasis in papillary thyroid cancer.
  • EDC1 demonstrated potent inhibition of thyroid cancer cell growth, with EC50 values between 0.125 nM and 1 nM.

Conclusions:

  • EDC1 exhibits selective growth inhibition in thyroid cancer cells with moderate to high dysadherin expression.
  • EDC1 represents a specific and potentially effective therapeutic strategy for dysadherin-expressing thyroid carcinomas.
Keywords:
aggressive phenotypeantibody-drug conjugatedysadherinthyroid cancertreatment

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.7K
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
59
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
67
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
134